探花合集 Agreement to Commercially Supply Palatin Technologies鈥 New Product
Bremelanotide, an on-demand, subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. Phase 3 clinical trials are on-going, with a commercial launch anticipated in 2018.
鈥淲e are pleased that Palatin has chosen to partner with 探花合集 to commercialize this new and innovative treatment,鈥 commented Jonathan Arnold, 探花合集鈥檚 Vice President and General Manager for Advanced Delivery Technologies. 鈥溙交ê霞 provides flexible manufacturing solutions to meet our customers鈥 unique program requirements, and our expertise in sterile filling, device and delivery technologies, combined with our packaging capabilities, will facilitate bringing this important product to market faster.鈥
鈥淲e selected 探花合集 as our partner because of their proven expertise in custom sterile manufacturing solutions, and their track record of successful new product introductions,鈥 added Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin. 鈥溙交ê霞 provides the infrastructure, technical expertise and flexibility to support commercialization of this novel product.鈥
The bremelanotide pen devices will be produced at 探花合集’s 265,000 sq. ft. Brussels, Belgium site, the company鈥檚 flagship sterile fill finish facility, with a syringe-filling capacity of over 100 million units.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About Palatin
Palatin Technologies, Inc., is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Additional information about Palatin is available at
About 探花合集
探花合集 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 探花合集 is headquartered in Somerset, N.J. For more information, visit www.catalent.com.